Abstract
Editorials21 June 2011Preemptive Pharmacogenetic Testing: Insufficient Data Equal Unsatisfactory GuidanceHoward L. McLeod, PharmD and Kim L. Isaacs, MD, PhDHoward L. McLeod, PharmDFrom University of North Carolina, Chapel Hill, NC 27599.Search for more papers by this author and Kim L. Isaacs, MD, PhDFrom University of North Carolina, Chapel Hill, NC 27599.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-154-12-201106210-00016 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The past decade has seen the emergence of tools for tailoring care to individual patients. Under the guise of personalized medicine, a host of drug-level assays and DNA, RNA, protein, and imaging tests promise to enhance clinical benefit by enabling clinicians to determine optimal therapies and dosages (1). These tools come at an opportune time, when health systems are under pressure to improve returns on the therapeutic investment. However, evidence on the clinical effectiveness and cost-effectiveness of preemptive testing is lacking.In this issue, Booth and colleagues (2) systematically review evidence (54 observational studies and 1 randomized trial) on a ...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
